219-221
Editorial
Pretreatment determination of TPMT – state of the art in clinical practice
A. Teml, E. Schaeffeler and M. Schwab
223-230
Clinical Trial
Changes in urinary PGE2 after ibuprofen treatment in preterm infants with patent ductus arteriosus
R. Antonucci, L. Cuzzolin, A. Arceri, A. Dessì and V. Fanos
231-237
Special Article
The effects of problem-based learning integration in a course on rational drug use: a comparative study between two Croatian medical schools
Robert Likic, Dinko Vitezic, Simon Maxwell, Ozren Polasek and Igor Francetic
239-247
Pharmacogenetics
Effect of genetic polymorphisms of CYP3A5 and MDR1 on cyclosporine concentration during the early stage after renal transplantation in Chinese patients co-treated with diltiazem
Yixi Wang, Changxi Wang, Jiali Li, Xueding Wang and Genglong Zhu, et al.
249-255
Pharmacogenetics
Relationships between thiopurine S-methyltransferase polymorphism and azathioprine-related adverse drug reactions in Chinese renal transplant recipients
Hua-Wen Xin, Hui Xiong, Xiao-Chun Wu, Qing Li and Lei Xiong, et al.
257-262
Pharmacogenetics
Distribution of TPMT risk alleles for thioupurine toxicity in the Israeli population
Edna Efrati, Lior Adler, Norberto Krivoy and Eli Sprecher
263-271
Pharmacokinetics and Disposition
Voriconazole drastically increases exposure to oral oxycodone
Nora M. Hagelberg, Tuija H. Nieminen, Teijo I. Saari, Mikko Neuvonen and Pertti J. Neuvonen, et al.
273-279
Pharmacokinetics and Disposition
The pharmacokinetic profile of recombinant human erythropoietin is unchanged in patients undergoing cardiac surgery
Stuart A. McCluskey, Wing K. Cheung, Rita Katznelson, Humara Poonawala and Ludwik Fedorko, et al.
281-285
Pharmacokinetics and Disposition
The CYP2C19 ultra-rapid metabolizer genotype influences the pharmacokinetics of voriconazole in healthy male volunteers
Guo Wang, He-Ping Lei, Zhi Li, Zhi-Rong Tan and Dong Guo, et al.
287-294
Pharmacokinetics and Disposition
Open AccessSt John’s wort extract (Ze 117) does not alter the pharmacokinetics of a low-dose oral contraceptive
Liane Will-Shahab, Steffen Bauer, Ullrich Kunter, Ivar Roots and Axel Brattström
295-301
Pharmacoepidemiology and Prescription
Starting insomnia treatment: the use of benzodiazepines versus z-hypnotics. A prescription database study of predictors
Anne M. Hausken, Kari Furu, Svetlana Skurtveit, Anders Engeland and Jørgen G. Bramness
303-308
Pharmacoepidemiology and Prescription
Drug use in pregnancy—physicians’ evaluation of quality and clinical impact of drug information centres
Sofia Kristina Frost Widnes and Jan Schjøtt
309-314
Pharmacoepidemiology and Prescription
Persistence of antimuscarinic drug use
Søren Brostrøm and Jesper Hallas
315-318
Debate Article
An analysis of the clinical development of drugs in Norway for the year 2000: the completion of research and publication of results
Ola P. Hole, Sigurd Nitter-Hauge, Henrik R. Cederkvist and Finn Ø. Winther
319-320
Letter to the Editors
Cytochrome P450 2C19
genetic polymorphisms in Ugandans
Jun Miura, Celestino Obua, Catherine Abbo, Sunao Kaneko and Tomonori Tateishi
321-322
Letter to the Editors
Hyperthermic intraperitoneal perfusion chemotherapy—views on the observed variability in oxaliplatin pharmacokinetics
Nuggehally R. Srinivas
323-324
Letter to the Editors
Hypotension due to the drug interaction of voriconazole with eplerenone and nifedipine
Jun Kato, Takehiko Mori, Yukinori Nakamura, Masatoshi Sakurai and Yoshinobu Aisa, et al.